Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ania Mikucka
Institution:
Boehringer Ingelheim (United States)
Observed institution:
Boehringer Ingelheim (United States)
ORCID:
0009-0004-2022-9520
Observed ORCID:
0009-0004-2022-9520
OpenAlex ID:
A5077839208
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
·
Cancer Research Communications
·
17
PDF
Supplementary Figure 7 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Data from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 1 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 1 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 8 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 3 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 3 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 5 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 5 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Data from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Data 3 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 6 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 8 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 6 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Table 5 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Table 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Table 1 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Table 1 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Table 4 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 4 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
FIGURE 4 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Supplementary Figure 4 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
2024
·
Robert J. Norgard
, Pratha Budhani
, et al.
Show more works
View as search
Works count:
32
Citation count:
18
H-index:
1
I10-index:
1
Year
Topic
Type